FDA DEVICE FACTS
BD Vacutainer® K2 EDTA Blood Collection Tubes
Becton, Dickinson and Company
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The intended use of the subject device is the same as the predicate with regard to the claims for collection and transportation of blood for in vitro diagnostic use. The subject device provides additional clarity on certain information consistent with current best practices (e.g., containment, preservation). The addition of HbA1c testing is not considered a new intended use because the subject and predicate devices are both intended for determination of analytes in whole blood. The proposed indication for use is equivalent to the indication cleared under K981013 except for explicitly stating for use with HbA1C testing. Despite this difference in the indications for use statements, the intended use for both the subject and predicate device is to provide a whole blood specimen for diagnostic evaluation. HbA1c is a diagnostic test completed on human venous whole blood sample.
Therefore, using K981013 as the predicate satisfies the requirement to have an appropriate predicate where both the subject and predicate devices have the same intended use.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。